AcquisitionOct 8, 2026Pending
Hot🇺🇸 United States
PBPacira BioSciences, Inc.VViatris Inc.
Healthcare › Pharmaceuticals
Equity value$1.65BEquity value
AnnouncedOct 8, 2026
ConsiderationCash
StructureTender offer
RegionNorth America
Cross-borderNo
Contingent paymentNo
Overview
Viatris Inc. agreed to acquire all of the outstanding shares of common stock of Pacira BioSciences, Inc. for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion, through a tender offer followed by a second-step merger for the same consideration.
Deal rationale
The acquisition adds two marketed, patent-protected, high-margin U.S. non-opioid pain medicines, EXPAREL and ZILRETTA, that are synergistic with Viatris' fast-acting meloxicam opportunity and advance its innovative medicines strategy.
AI-generated from the SEC filingPendingHealthcare › PharmaceuticalsUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | $1.65B | Headline figure |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Cash |
Advisors
Buy-side
CPCenterview PartnersMSMorgan Stanley
Sell-side
GSGoldman Sachs
Parties
Target
PBPacira BioSciences, Inc.
- Headquarters
- United States
- Ticker
- PCRX
Acquirer
VViatris Inc.
- Headquarters
- United States
- Ticker
- —